Generic Medicine Info
Indications and Dosage
Resectable gastric carcinoma
Adult: In combination with tegafur and oteracil potassium: 40 mg/m2 BSA bid for 7 days pre-operatively and for 15 days after operation starting on day 15 after operation.
Hypersensitivity, Pregnancy and breast-feeding.
Special Precautions
Cardiac, renal or hepatic impairment. Monitor CBC durring chemotherapy.
Adverse Reactions
Fatigue, diarrhoea, constipation, sore mouth, hair thining, rash, loss of appetite, change in taste, headaches, insomnia, brittle nails, photosensitivity, confusion, drowsiness.
Potentially Fatal: Bone marrow suppression during chemotherapy.
Drug Interactions
May cause changes in INR readings when used with warfarin. May raise serum phenytoin levels when used concurrently.
Description: Gimeracil strongly inhibits dihydropyrimidine dehydrogenase, and inhibits 5-FU degradation approximately 180 times more effectively than uracil in vitro. Coadministration of gimeracil and tegafur markedly increases the antitumor activity of tegafur.
MIMS Class
Cytotoxic Chemotherapy
Disclaimer: This information is independently developed by MIMS based on Gimeracil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in